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Abstract
Brain repair involves a compendium of natural mechanisms that are activated following stroke. From a therapeutic viewpoint, reparative thera-
pies that encourage cerebral plasticity are needed. In the last years, it has been demonstrated that modulatory treatments for brain repair such
as trophic factor- and stem cell-based therapies can promote neurogenesis, gliogenesis, oligodendrogenesis, synaptogenesis and angiogenesis,
all of which having a beneficial impact on infarct volume, cell death and, finally, and most importantly, on the functional recovery. However,
even when promising results have been obtained in a wide range of experimental animal models and conditions these preliminary results have
not yet demonstrated their clinical efficacy. Here, we focus on brain repair modulatory treatments for ischaemic stroke, that use trophic factors,
drugs with trophic effects and stem cell therapy. Important and still unanswered questions for translational research ranging from experimental
animal models to recent and ongoing clinical trials are reviewed here.
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Brain repair after ischaemic stroke
Protective therapies that focused on saving just the neural cells
instead of protecting all the components of the neurovascular unit
have consistently failed [1]. Rather than being simple, recovery from
ischaemia is a complex and highly dynamic process that includes not
only injury and response signals within the lesions but also active self-
repair processes that occur in the whole organ [2–5] and that should
be precisely synchronized for tissue remodelling. Neurogenesis, glio-
genesis, oligodendrogenesis, synaptogenesis and angiogenesis are
brain repair-associated processes that are activated following stroke.
In recent decades, animal models of cerebral ischaemia and clinical
research have demonstrated how brain repair processes can be
actively modulated by the administration of both trophic factors and
stem cells.
We should first consider that protection and repair mechanisms
are activated and work together from the very beginning of cerebral
ischaemia (Fig. 1). The accompanying hypoxia and glucose
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deprivation, cell death programs and immunological events of ischae-
mia are initiated to remove damaged cells and tissue debris and to
prepare injured areas for repair processes [6–8] and as a response to
injury, transcriptional programs associated with axonal sprouting,
survival and myelin formation are activated and maintained from the
very beginning [9, 10]. Research is now focused on how to modulate
these processes to preserve all the structures that make up the
neurovascular unit, including microvessels and pericytes (vascular
protection), neurons and their axons (neuroprotection), astrocytes
and other supportive cells such as oligodendroglia [11].
Synchronized events after damage may allow initial deleterious
signals to transition into beneficial effects and recovery [12]. Dur-
ing the early acute phase, blood-brain barrier disturbances pre-
dominate and matrix proteases like MMP-4 or MMP-9 are
essential for neurovascular remodelling, while during the late
phase, other processes, such as angiogenesis, may provide the
critical substrate for remodelling. Understanding how neurovascu-
lar signals and substrates make the transition from initial injury to
angiogenic recovery is important for obtaining new therapeutic
options as a cerebral infarct is a highly complex condition whose
effects might extend beyond time (time since the ischaemic insult)
and location (communication between brain ischaemic regions and
healthy areas).
Trophic factors, stem cell therapy and rehabilitation have all been
shown to exert potential therapeutic effects by modulating brain
repair- associated mechanisms (Fig. 2). In experimental animals,
increased levels of neurogenesis, gliogenesis, oligodendrogenesis
and angiogenesis accompanied with better functional recovery have
been widely reported after treatment [13, 14]. Such promising pre-
clinical results have led to multiple clinical trials in the last years. In
this review, we will discuss recent reports from both pre-clinical and
clinical studies that raise important new questions and concerns for
further advances in the field.
Trophic factor-based therapies
The discovery of nerve growth factor (NGF) in the 1950s by Levi-
Montalcini and Hamburger [15] opened a promising new era in physi-
ology in which the growth-factor induced regeneration of damaged
tissues seemed to be possible and its therapeutic potential has been
explored in both experimental animals and clinical trials (Table 1). As
could expected, new hopes and fundamental questions have emerged
over the last years. This approach could be based on the direct
administration of trophic factors, and of drugs with trophic effects.
Experimental animal models
Trophic factors. The reported number of biological modulatory
molecules that mediate in brain repair is high and ever-growing.
Besides NGF, which has been reported to improve cholinergic func-
tion, stimulate axonal growth, cerebral perfusion and neurogenesis by
stimulating proliferation through tyrosine kinase receptor signalling
[16, 17], the administration of other factors, like basic fibroblast
growth factor (bFGF), has been shown to promote neurogenesis in
both intact and ischaemic brain [18]. Indeed, intracysternal adminis-
tration 1 day after experimental stroke in rats has been shown to
stimulate progenitor cell proliferation in the subventricular zone (SVZ)
and dentate gyrus (DG), important areas for the development of new
neurons in the adult brain [19]. While higher levels seem to be
required after damage [9], it is important to emphasize that trophic
factors not only act in disease but also under normal conditions to
Fig. 1 Pathogenic mechanisms and thera-
peutic options in cerebral infarct. Time
line for the mechanisms and therapy
involved in endogenous protection and
brain protection-repair after ischaemic
stroke. MSCs: mesenchymal stem cells;
UCBCs: umbilical cord blood cells; DSCs:
dental stem cells; ESCs: embryonic stem
cells; BMSCs: bone marrow stem cells;
NSCs: neural stem cells; G-CSF: granulo-
cyte colony-stimulating factor; VEGF: vas-
cular endothelial growth factor; BDNF:
brain-derived neurotrophic factor; NGF:
nerve growth factor; bFGF: basic fibroblast
growth factor; IGF-1: insulin growth fac-
tor-1; EPO: erythropoietin.
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maintain tissue homeostasis. This has been reported in brain-derived
neurotrophic factor (BDNF) signalling, impairment of which may
cause progressive neuronal dysfunction in animal models [20]. In this
sense, intravenous administration of BDNF during the 5 days follow-
ing cortical photothrombotic stroke is associated with enhanced
migration of progenitor cells from the SVZ and increased neurogene-
sis in the DG on DCX- and NeuN-stained slices [21].
How can brain repair be modulated by the action of factors like
BDNF? Although still unclear, white matter glial cells have been
reported to play a key role in protecting and promoting the regenera-
tion of nerve fibres by producing BDNF itself [22]. Also, prostacyclin,
an important hormone released in response to vascular damage is
stimulated around cerebral arteries when this factor is present [23].
From a genetic perspective, it is known that BDNF can activate NF-kB
through the TrkB-PI3-Kinase-Akt pathway [24] and that this activation
leads to the downstream activation of genetic programs that contrib-
ute to protecting cells from stress conditions such as serum starva-
tion, glutamate toxicity or ischaemia [25], all of which occur at the
beginning of the ischaemic insult.
It bears mentioning that trophic factors not only enhance single
processes like neurogenesis, but they also exert pleiotropic effects on
other biological pathways such as vascular function, immune cell
function or cell death. In this sense, it was recently reported that the
preserved neuronal loss and reduced number of TUNEL-positive cells
after intranasal administration of BDNF might also be due to modula-
tion of local inflammation by this factor, which would reduce tumour
necrosis factor-a (TNF-a) levels and augment those of interleukin
(IL)-10 [26].
However, in addition to all of this pleiotropic interplay, the activity
of most of these factors within the brain under ischaemic conditions
is not clear. After the hypoxic insult, many hypoxia-response genes
such as HIF-1alpha are upregulated, triggering downstream changes
in other interacting genes such as vascular endothelial growth factor
(VEGF), which is the key gene for the angiogenesis induced in
penumbral regions of the brain. This angiogenesis is known to
depend on several factors including VEGF, VEGFR2, Angiopoietins 1
and 2 and its Tie2 receptors [27]. In a recent study, inhibition of VEGF
receptor 2 after ischaemia worsened injury and also affected cell
death patterns with a shift from apoptosis to a necrosis phenotype
[28]. In many other studies in which VEGF was administrated follow-
ing stroke, the growth factor was shown to enhance brain repair pro-
cesses [29, 30]. For all these reasons VEGF and its signalling of
vasculogenesis has attracted much interest in recent years, revealing
that neurogenesis is not the only process that responds to trophic
factor therapy among possible brain repair therapies. Indeed, some
trophic factors such as insulin growth factor-1, which has been
reported to promote recovery after stroke [31–33], exert their activity
in different routes by enhancing endothelial function, regulating apop-
tosis and having anti-inflammatory properties instead of just affecting
neurogenesis [34, 35].
Another process that is modulated by brain repair therapies is
myelin formation. Again, we emphasize the importance of connec-
tions between elements of the different pathways involved in brain
repair after ischaemia. Recent publications have suggested connec-
tions within signal transduction pathways between elements such as
Lingo-1 and epidermal growth factor [36]. Given that Lingo1 antibod-
ies can promote recovery from demyelinating disease in animal mod-
els [37], trophic factors that might modulate Nogo-A or Lingo1
activities may offer interesting possibilities for brain repair. Important
inhibitors of axonal remodelling, such as Nogo-A, are augmented
after cerebral ischaemia [38] and their inhibition through viral-medi-
ated RNAi enhances axonal connectivity [39]; therefore, strategies
that enhance myelin formation and axonal remodelling through tro-
phic factors are a possible way forward in stroke research.
Other possible treatment approaches are blood-mobilizing drugs
like erythropoietin (EPO) [40–42] or Granulocyte colony-stimulating
factor (G-CSF), which have been shown to have positive results in ani-
mal models [43, 44]. Interestingly, higher levels of neovascularization
Fig. 2 Brain repair therapies through brain
plasticity enhancement. Mechanisms
underlying cerebral plasticity associated
with repair processes. G-CSF: granulocyte
colony-stimulating factor; VEGF: vascular
endothelial growth factor; BDNF: brain-
derived neurotrophic factor; NGF: nerve
growth factor; bFGF: basic fibroblast
growth factor; IGF-1: insulin growth fac-
tor-1; EPO: erythropoietin; MSC: mesen-
chymal stem cells; UCBC: umbilical cord
blood cells; DSC: dental stem cells; ESC:
embryonic stem cells; BMSC: bone mar-
row stem cells; NSC: neural stem cells.
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and endogenous stem cell biological activity were observed when
these factors were combined in a recent study [45]. In light of these
results, an open question in trophic factor therapy is whether aug-
mented efficacy could be obtained by applying these factors in specific
combinations instead of using any one factor alone.
On the other hand, some other drugs with trophic effects, like
CDP-choline, which have been attributed with a protective role [46,
47], have come under investigation. Although its mechanisms of
action are unknown, it is thought that CDP-choline improves both the
structural integrity and functionality of the neuronal membranes, and
this may in turn assist membrane repair [48]. Experimental animal
studies have demonstrated that CDP-choline not only promotes pro-
tective mechanisms (decreasing gliosis and cell death) but also
seems to stimulate repair (increasing endogenous cellular prolifera-
tion, angiogenesis and synaptogenesis) [49]. Another drug that has
been attributed with a protective role is Cerebrolysin, which has
exhibited trophic properties when applied 24 and 48 hrs after stroke
in animal models of ischaemia [50]. Indeed, while infarction volume
does not seem to be substantially reduced with this treatment, the
functional outcome is improved and proliferation, migration and
Table 1 Main results of therapeutic studies with trophic factors or drugs with trophic effects in cerebral infarct animal models and human
clinical trials
Animal models Clinical trials
Trophic factors
Basic fibroblast
growth factor
(bFGF)
Promotes neurogenesis [18]
Enhances functional recovery and stimulates
progenitor cell proliferation [19]
Phase III (286 patients). Prematurely stopped [53]
Brain-derived
neurotrophic
factor (BDNF)
Cellular and functional recovery [21]
Protects and promotes nerve fibreregeneration [22]
Promotes prostacyclin biosynthesis [23]
No studies
Vascular endothelial
growth factor
(VEGF)
Reduces neuronal cell death, increases angiogenesis
and vascular permeability [116, 117] reduces infarct
volume, improves behavioural recovery [30]
No studies
Erythropoietin
(EPO)
Reduces infarct size and improves neurobehavioral
deficits [41]
Safety: open label (13 patients); Efficacy: double-blind
randomized proof of concept trial (40 patients):
Improvement in neurological outcome, and smaller
lesion size [55]
Phase II/III (522 patients): negative results and safety
concerns [56]
Granulocyte
colony-stimulating
factor (G-CSF)
Promotes new blood vessel formation, has anti-
inflammatory, anti-excytotoxic, neuroprotective
properties [43] and survival-enhancing capacity and
effects on functional outcome [44]
Safety: Phase IIb (60 patients): [58]
Safety and efficacy: AXIS-2 Trial finished. Results not
yet published
EPO + G-CSF Enhances angiogenesis and tissue plasticity, leading to
greater functional recovery [45]
No studies
Drugs with trophic effects
CDP-choline
(citicoline)
Increases neuronal plasticity and contributes to
sensorimotor function recovery [48]
Promotes protective and repair mechanisms [46, 47,
49]
Efficacy and safety: Individual pooled data analysis
[61]
Efficacy: Phase III (ICTUS Trial; 2078 patients)
finished [62]. Results not yet published
Porcine brain
derived peptide
(cerebrolysin)
Reduces infarct volume and improves recovery [50]
with increased neurogenesis [51], efficacy in
neurological recovery, reduction of neuronal death,
increased cell proliferation and decreased
inflammatory response [52]
Safety and efficacy: Phase II clinical trial (146
patients) [63] and Cochrane Syst Rev [64]: not
enough evidence for efficacy. No safety concerns
Safety and efficacy: Phase IV Clinical trial finished:
CASTA (1070 patients) safety confirmed; possible
efficacy in more severe strokes [66]
A non-systematic selection of the main results of therapeutic studies with trophic factors or drugs with trophic effects in animal models and
clinical trials of cerebral ischaemia is provided. The reference number for each study is shown in brackets. Information from ongoing clinical tri-
als can be consulted in the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and clinical trials (http://clinicaltrials.gov/) databases.
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survival of neuroblasts, especially in the peri-infarct area, have been
thought to contribute to the observed results [51, 52].
Clinical studies
Some of the trophic factors mentioned above, including bFGF, EPO
and G-CSF, have been tested in controlled human clinical trials
(Table 1). Unfortunately and in contrast with the experimental stud-
ies, the results have been mixed. As an example, a phase III clinical
trial for intravenous bFGF administration for acute ischaemic stroke
was stopped because an interim analysis of efficacy data predicted
too small a chance of demonstrating a statistically significant benefit.
In addition, unexpected peripheral side effects including leucocytosis
and decreased blood pressure were reported in the treated group
[53]. Nevertheless, new trials are still being considered as the pre-
clinical data continue to justify further controlled clinical research with
larger cohorts of patients [54].
In the case of EPO, the results are also inconclusive. While an ini-
tial small-size proof of concept trial performed in acute stroke patients
reported an improvement in stroke outcome at 1 month and signifi-
cantly smaller lesion size in the treated group than in controls without
relevant side effects [55], a larger phase II/III study with EPO ended
with negative results and safety concerns [56]. The possibility that
some of these factors could be especially interesting for specific
stroke subtypes is also not clear at the moment. Peripheral blood
mobilization factors like G-CSF have been tested in humans and have
been found to be safe [57, 58]. In addition, an exploratory analysis has
suggested dose-dependent beneficial effects from G-CSF treatment in
patients who had large baseline diffusion-weighted image lesions,
supporting further investigation and repeated trials with larger cohorts
of patients [59]. An AXIS-II trial investigating the safety, tolerability
and effect of G-CSF in acute ischaemic stroke patients has recently
completed recruitment but results have not yet been published [60].
Based on their pre-clinical results, other drugs with trophic
effects, specifically CDP-choline and Cerebrolysin, have also been
tested in clinical trials. A meta-analysis of pooled data collected from
several small phase III trials, concluded that CDP-choline was
reported to be safe and present a certain efficacy. In patients with
moderate to severe ischaemic stroke, oral CDP-choline for 6 weeks
increased the global odds of recovery at 3 months by 33% compared
with the placebo [61] and this is being studied more thoroughly in a
larger clinical phase III trial (ICTUS) [62], which has recently com-
pleted recruitment with results to be published soon [60]. In the case
of Cerebrolysin, a randomized placebo-controlled trial (146 patients)
showed a significant improvement of cognitive function of patients
treated with Cerebrolysin, but without a significant effect on neurolog-
ical or functional outcome [63]. A systematic Cochrane review
reported not enough evidence to evaluate the effect of cerebrolysisn
on survival and dependency in acute ischaemic stroke with no safety
concerns [64], a large double-blind placebo-controlled randomized
phase III clinical trial (1070 patients) conducted in Asiatic patients
(CASTA), confirmed its safety and suggested a benefit for the group
with more severe strokes [65, 66]. Thus, it could be interesting to
continue the research development of this drug.
In summary, to date there is insufficient knowledge of efficacy of
trophic factors in ischaemic stroke based on clinical trials, and the
publication of the results of the AXIS-II trial should give more infor-
mation. On the other hand, research on drugs with trophic effects has
demonstrated the safety of CDP-choline and of Cerebrolysin, and sug-
gests some efficacy in acute ischaemic stroke.
Stem cell therapies
As well as immune-modulation and substitution of damaged areas
under certain conditions [27, 67], the available evidence supports the
concept that stem cells assist recovery by modulating brain repair pro-
cesses, including neurogenesis, gliogenesis, synaptogenesis and
angiogenesis. While the molecular events underlying these processes
are mostly unknown, it has been suggested that stem cells are capable
of secreting trophic factors (VEGF, bFGF, BDNF) [68], in response to
repair processes amplifying their levels in the brain. After culture in ex-
vivo experiments, trophic interactions between MSCs and ischaemic
brain have led to increased production of trophic factors including
BDNF, VEGF or HGF (hepatocyte growth factor) [69] and it is known
that stem cells express receptors that might allow these interactions
[70, 71]. Furthermore, it has been discovered that stem cell transplan-
tation is more effective when implanted cells are derived from stroke
animals than when harvested from controls [72]. This recent report
supports the hypothesis of trophic interactions between damaged
brain and stem cells under ischaemic conditions that would prepare
stem cells to exert their positive function. Interestingly, if these trophic
interactions exist, another treatment strategy might be to combine
stem cell therapy methods with trophic factor pre-treatment in vitro
before their application. Under this perspective, stem cells genetically
modified to overexpress specific trophic factors might enhance neuro-
nal differentiation and survival [73]; in addition, gene modification of
MSCs using viral vectors or RNA-based techniques may be a key to
obtaining enhanced expression of specific desired factors (i.e. FGF-2)
in comparison with ‘wild type’-MSC transplantation [74].
Four major aspects will be reviewed below, concerning: (i) stem
cell sources; (ii) the type of cell transplant, based on cell source; (iii)
the time of administration or therapeutic window; and finally, (iv) the
most suitable administration route for its clinical translation.
Looking at the wide range of stem cell sources, cerebral ischae-
mia can be treated using different types of cells from different origins
(see Table 2). Enhanced function has been reported with different cell
populations under different experimental conditions [75, 76].
Although a variety of conditions have been proposed for cell therapy,
there is still no proven stem cell-based approach for stroke treatment
and substantial symptomatic relief has not yet been demonstrated in
patients [67, 76, 77].
Experimental animal models
In experimental animal models, neural stem cell (NSC) administration
has been shown to enhance axonal sprouting and transport, dendritic
activity and the expression of neurogenesis, gliogenesis and
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neurotrophic support-associated genes [78–81]. While infarct size is
not significantly reduced, levels of cell death and Bax-positive cells
are decreased after 7 days of treatment in these experimental animals
while Bcl-2 expression in the penumbra is augmented and neurologi-
cal function is improved [82]. This is also observed when using other
non-neural stem cell sources such as bone marrow (BMSC), umbilical
cord blood cells (UCBC) or mesenchymal stem cells (MSC). Indeed,
bone marrow mononuclear cell (BMMC) transplantation can promote
proliferation of the endogenous NSCs and this is observed concomi-
tantly with increased proliferation of endothelial cells (angiogenesis)
following ischaemic stroke [83]. Endogenous NSC can be found
around the peri-infarct area adjacent to endothelial cells, so it has
been suggested that at least some NSCs are originated from micro-
vascular pericytes. The mechanisms involved in the endogenous neu-
rogenesis and vasculogenesis after BMC administration are still
unclear and therefore under investigation.
Meanwhile, bone marrow-derived MSC [84] also hold great prom-
ise for cell therapy. The beneficial effects of MSC administration in
experimental animal stroke models is well-described and there are a
variety of studies with similar good results in structural/functional
recovery [73, 85, 86]. A recent review summarizes the role of thera-
peutic mobilization of transplanted bone marrow stem cells and its
importance for brain plasticity and remodelling in stroke [87]. Adi-
pose tissue like bone marrow, is another source of MSC in which
interest is growing because it provides an abundant, ethically unpro-
blematic and accessible source of cells with similar potential to that
of other adult stem cells [88, 89]. The same can be said of placenta
cells, which also have low immunogenic properties and are easily
obtained [90, 91]. In vivo, bioactive molecules secreted by MSCs pro-
vide a regenerative microenvironment that enhances a self-regulated
regenerative response. This regenerative microenvironment (trophic
activity) mediates tissue repair and regeneration under ischaemia
conditions [92].
As was previously mentioned, endothelial cell regeneration and
neovascularization after tissue ischaemia are subjects of interest now-
adays in the context of brain repair and it has been reported that
repair can be enhanced by the administration of endothelial progeni-
tor cells (EPCs), the positive effects of which have been observed in
long-term neurobehavioural tests [93, 94].
Lastly, another ethically unproblematic source of cells with great
potential are inducible pluripotent stem cells (iPS). First described by
the Yamanaka group [95], this kind of approach, combined with
transplantation onto biodegradable matrices could provide an inter-
esting framework for stem cell-based therapies [27]. In previous
reports, iPS treatment has been shown to improve motor function,
reduce infarct size, attenuate inflammatory cytokines and mediate
protection [96]. However, as a therapeutic option, iPS cells require
further evaluation in light of their high tumourigenic potential under
certain conditions, a major concern for clinical use [67, 97].
Independently of the above-mentioned cell sources, an important
practical issue is the type of transplant: autologous (same individual),
allogenic (same species) or xenogenic (another species). To prevent
rejection, autologous administration can be considered the best
option. A limitation of this approach in a clinical situation is that it
would only allow treatment several weeks after the stroke, as this is
the time needed for the cultivation and expansion of cells from the
donor [98]. However, as the most appropriate time for administering
stem cells is not clear and pre-clinical data also indicate that acute all-
ogenic administration is both safe and effective [99], it might be pos-
sible to consider the creation of biobanks of allogenic stem cells
(donors) to treat cerebral infarct patients earlier, within the acute
phase time period.
To emphasize results from a clinical perspective, the route of
administration for stem cells is still a major concern. There are sev-
eral possible options which have been tested in experimental animals
including intrastriatal, intraventricular, intravenous [100], intracarotid
[101] or intranasal routes [102]. Some of them have an apparently
similar effectiveness, but intravenous administration would be the
least invasive delivery mode for use in future clinical applications
[99]. However, as stroke is a localized CNS disease, new options and
ideas in CNS-directed delivery are desirable. Also, new implantation
sites such as the epi-cortical implant, a new minimally invasive
method [103] or also the plexus-CSF route [104], would minimize or
eliminate the distribution of graft cells to peripheral organs and obvi-
ate the need for a surgical (cell) implantation that is required by the
Table 2 Brief summary: stem cell types
ESC (embryonic stem cells): Pluripotent self-renewing stem cells
derived from the inner cell mass of embryos
IPS (inducible pluripotent stem cells): Adult somatic stem cells
derived from normal adult tissues modified through genetic
engineering; They resemble pluripotent stem cells and have self-
renewing potential
NSC (neural stem cells): Self-Renewing cells capable of differentiating
into the most relevant brain cell types (neurons, astrocytes,
oligodendrocytes)
BMSCs (bone marrow stem cells)
HSCs (hematopoietic stem cells, CD34+). Heterogeneous
populations of multipotent cells capable of differentiating into all
blood cell types (both myeloid and lymphoid)
EPCs (endothelial progenitor stem cells, CD34+). Circulating blood
cells capable of differentiating into endothelial cells
(angiogenesis)
MSCs (Bone Marrow Mesenchymal Stem Cells, CD34).
Multipotent stem cells from circulating blood with recently
discovered reparative potential in damaged tissues.
MSC (mesenchymal stem cells)
ASC (adipose-derived MSCs). Mesenchymal stem cells highly
concentrated in adipose tissues
pMSC (placental MSCs). Mesenchymal stem cells from the
placenta
UCBs (umbilical cord blood MSCs). Mesenchymal stem cells in
umbilical cord blood
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intracarotid route. Either way, studies in experimental animals should
focus on imaging and cell tracking of the transplanted cells.
Taking into consideration that in patients acute stroke is usually
considered a ‘time is life’ condition, the time of transplant is critical,
and, for now, there is no clear concordance between animal models
and humans. It has been described that the blood-brain barrier is
open continuously for several weeks after ischaemia [105], indicating
that the injured tissue may permit the entrance of exogenous cells
during a long post-ischaemic window and this possibility has resulted
in most studies having been focused on post-acute MSC
administration [73]. However, with these long experimental
conditions it is not possible to evaluate the protective effects, if any,
of these cells and whether early administration might interact with
reparative modulation in the brain. Furthermore, gliogenesis could
also have a detrimental role as glial scarring in the late state of
cerebral infarct may impede or compromise the delivery of new cells
to the peri-infarct areas where they could exert their positive function.
Clinical studies
Globally and in contrast to results from experimental animal models
(Table 3), clinical trials with stem cells have reported safety but
mixed results in terms of efficacy [106]. As an example, cultured
human (h) NSCs stereotactically implanted in patients with motor def-
icits, did not produce evidence of a significant benefit in terms of
motor function although safety and feasibility was confirmed [107].
With regards to MSCs, some studies have reported that they can
be safely transplanted into the brain of patients with excellent toler-
ance and without complications [108]. Also systemically, in patients
with severe cerebral infarcts, intravenous infusion of autologous
MSCs appears to be a feasible and safe therapy [109] that may
improve functional recovery [98]. A long-term follow-up study has
shown the safety of the treatment after 5 years [110], this kind of
positive result is interesting and the study should be replicated with
larger cohorts of patients.
Currently, there are open clinical trials using MSCs in ischaemic
stroke. Phase I and phase II studies exist for BMMCs and results will
be obtained soon. Other studies are evaluating the feasibility and tol-
erance of the intravenous injection of autologous MSCs in phase II
and another 2 clinical trials in phase I/II are evaluating the intravenous
injection of allogenic MSCs [60]. There are considerable difficulties in
designing future efficacy trials, some of which are inherent to the field
of regenerative treatment in stroke, and others specific to stem cells
or their mode of delivery [111].
As has been discussed above, multiple subtypes of stem cell ther-
apies have been developed in recent years for the treatment of cere-
bral ischaemia. However, large and well-designed trials are needed to
identify the best options for their transfer to the clinical setting [112].
In 2007, the Stem Cell Therapy as an Emerging Paradigm for Stroke
Table 3 Main results of stem cells in animal models and cerebral infarct clinical trials
Animal models Clinical trials
Stem cells
Neural stem
cells (NSCs)/
neuronal cells
Promotes behavioural recovery and endogenous
neurogenesis [79], reduces infarct volume [80]
enhances axonal sprouting and the expression of
genes involved in neurogenesis, gliogenesis, and
neurotrophic support; modulates microglial response
[118]. Anti-apoptotic activity [82]
Phase II (18 patients): No evidence of a significant benefit in
motor function but safety and feasibility demonstrated in
[107]
Safety of a manufactured neural stem cell line (CTX0E03) is
being tested (PISCES study, Phase I)
Mesenchymal
stem cells
(MSCs)
Enhances structural/functional recovery [85], reduces
lesion volume, decreases inflammatory cell
proliferation [86, 88]
Stereotactic implantation:
Safety: Open study (5 patients): with excellent tolerance [108]
Intravenous administration:
Safety: Open label (12 patients): no safety concerns [109]
Safety and efficacy:
Phase I/II (30 patients) no adverse events and better
outcomes in MSC-treated patients [98]
Open label long-term follow-up (52 patients): safe and clinical
improvement [110]
Bone marrow
stem cells
(BMSCs)
CD34: enhanced neovascularisation, neurogenesis,
functional recovery [119]
EPCs: protected the brain against ischaemic injury,
promoted neurovascular repair and improved long-
term neurobehavioural outcomes [93]
Safety: Ongoing Phase I and Phase II trials. CD34: autologous
CD34+ subset BMSC infusion and intercerebral implantation
Main results of stem cell therapy in animal models and clinical trials of cerebral ischaemia. The reference number for each study is shown in
brackets. Information from ongoing clinical trials can be seen in the PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and Clinical trials (http://
clinicaltrials.gov/) databases.
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(STEPS) meeting was organized to accelerate the field of cell therapy
for stroke and to address outstanding questions [113]. In 2010, a
second meeting, STEPS2, was held. Participants identified critical
gaps in knowledge and research areas that require further studies,
updated existing guidelines and drafted new recommendations to cre-
ate a framework to guide future investigations into cell-based thera-
pies for stroke [114]. In summary, larger trials with stringent and
well-delimited inclusion criteria are necessary as the results from pre-
clinical studies still support significant beneficial effects from cell
therapy. Furthermore, a better understanding of cell fate following
infusion in patients is desirable.
In our opinion, as suggested in a recent review by our group
[115], and based on the lack of expression of MHC class II antigens,
the use of allogenic mesenchymal stem cells [99] may broaden thera-
peutic interest in their use. This type of cell has been shown to be a
good alternative for treating patients with cerebral infarction in the
acute phase. Also the IV administration route is the least invasive and
may offer the most suitable strategy for its clinical translation. Their
administration during the acute phase could help to inhibit the first
steps of the ischaemic cascade after stroke and enhance endogenous
mechanisms of brain repair. Therefore, for the authors, the IV admin-
istration of mesenchymal stem cells in the acute phase amplifies the
resources for good functional recovery and may be an effective ther-
apy in the future.
Last comments
In cerebral ischaemia, protection and brain repair mechanisms are
activated and orchestrated as a continuum once the disease process is
initiated. Both trophic factors and stem cell therapy have been shown
to modulate genetic and molecular programs underlying neuronal cell
survival and axonal connectivity, angiogenesis, oligodendrogenesis
and modulation of inflammation. Both therapeutic approaches have
consistently shown exciting results in experimental animal models but
their efficacy in patients has not yet been confirmed. Although not
entirely understood, recent data have demonstrated paracrine interac-
tions between stem cells and trophic factors, and this could suggest a
multi-modal strategy for brain repair. Experimental research in the
coming years will be focused on combining both approaches. At the
same time, protocolizing the clinical context, dose, times and routes of
administration will help design more effective clinical trials.
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